Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03063489 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability
A Phase 1 study of Eye Pain, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 6
- Study locations
NCT03063489 is a Phase 1 study of Eye Pain that has completed, run by Bausch Health Americas. The registered enrollment target is 15 participants. The trial reports 6 study locations across 5 states.
The verdict
NCT03063489, a Phase 1 study of Eye Pain, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 6
- Study locations
Study Summary
Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Instillations of Loteprednol Etabonate Ophthalmic Gel, in Normal Healthy Volunteers
Conditions Studied
Interventions
- DRUG Loteprednol Etabonate Ophthalmic Gel
Study Locations (6)
Missouri
- Valeant Site 06 - Kansas City
- Valeant Site 02 - St Louis
Arizona
- Valeant Site 01 - Phoenix
California
- Valeant Site 03 - Oceanside
Florida
- Valeant Site 05 - Miami
Massachusetts
- Valeant Site 04 - Quincy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-02 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03063489
The ClinicalTrials.gov registry entry for NCT03063489 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Eye Pain appearing as the primary indexed condition, and to 1 intervention - of which Loteprednol Etabonate Ophthalmic Gel is the first listed.
NCT03063489 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Missouri, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT03063489 about?
NCT03063489 is a clinical study titled "Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability". Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Instillations of Loteprednol Etabonate Ophthalmic Gel, in Normal Healthy Volunteers
What is the current status of trial NCT03063489?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2015-02. Estimated completion is 2015-07.
What conditions does trial NCT03063489 study?
This clinical trial studies the following conditions: Eye Pain.
What interventions are being tested in trial NCT03063489?
The interventions under investigation include: Loteprednol Etabonate Ophthalmic Gel (DRUG).
Who is sponsoring clinical trial NCT03063489?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03063489 being conducted?
This trial has 6 study locations across Arizona, California, Florida, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eye Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.